Clinical trials: Disorders of Breast
Metastatic Breast Cancer
An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory
This expanded access program is an open-label, multi-center study, which will consist of a PreTreatment Phase and a Treatment Phase.
- Trial name
- NCT01240421
- Testing
- Eribulin Mesylate
- Where
- 14 sites in Belgium, Canada and 1 more
- Sponsor
- Eisai Inc.
Advanced/Metastatic Solid Tumors
Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors
Phase I, first-in-human, open-label, multicenter, dose-escalation and dose expansion study with the aim of exploring safety, tolerability and preliminary antitumor activity of NMS-03305293 (a PARP inhibitor) as single agent in…
- Trial name
- NCT04182516
- Testing
- NMS-03305293
- Where
- 10 sites in United States, Bulgaria and 3 more
- Volunteers
- 52 people
- Sponsor
- Nerviano Medical Sciences
Breast Cancer
Comparison of the Philips MicroDose Tomosynthesis System to 2D Digital Mammography
The primary objective of this study is to compare the safety and clinical performance of the Philips MicroDose Tomosynthesis system images and images from FFDM systems.
- Trial name
- NCT02615509
- Testing
- Imaging on experimental tomo device
- Where
- United States
- Volunteers
- 347 people
- Sponsor
- Philips Digital Mammography Sweden AB
Moderate to Severe Cyclic Mastalgia
An Open-Label, MultiCenter Evaluation of the Use of Topically Administered FP1198 in Subjects With Pain Associated With Cyclic Mastalgia
The purpose of this study is to determine the safety of topical FP1198 for the treatment of moderate to severe cyclic breast pain (cyclic mastalgia) and to examine the clinical activity of FP1198.
- Trial name
- NCT01105793
- Testing
- Danazol
- Where
- 4 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- FemmePharma Global Healthcare, Inc.
Breast Neoplasms
A Phase II Study of CI-1033 in Treating Patients With Metastatic (Stage IV) Breast Cancer
CI-1033 is an experimental drug that acts as an inhibitor of erbB (EGFR) receptors, which may be involved in tumor growth. The primary objective of this study is to assess the antitumor activity of CI-1033 in patients with…
- Trial name
- NCT00051051
- Testing
- CI-1033
- Where
- 66 sites in United States, Belgium and 7 more
- Volunteers
- 168 people
- Sponsor
- Pfizer
Breast Cancer
Heat-Activated Target Therapy of Local-Regional Relapse in Breast Cancer Patients
The 105-15-201 study is designed to assess the effectiveness and tolerability of the combination of heat-activated target therapy (radiotherapy + hyperthermia + lyso-thermosensitive liposomal doxorubicin) of loco-regional relapse…
- Trial name
- EURO-DIGNITY (NCT02850419)
- Testing
- ThermoDox (Thermally Sensitive Liposomal Doxorubicin), Radiation Therapy, Superficial Hyperthermia
- Where
- 3 sites in Czechia, Israel and 1 more
- Sponsor
- Imunon
Bone Cancer, Bone Metastases
Focused Ultrasound Surgery in the Treatment of Pain Resulting From Metastatic Bone Tumors With the ExAblate 2100 Conformal Bone System
The goal of this prospective, non-randomized, single-arm, phase 2 study is to evaluate the safety and effectiveness of this treatment using this ExAblate conformal system in the treatment of pain resulting from metastatic bone…
- Conditions
- Bone Cancer, Bone Metastases, Pain
- Trial name
- NCT01085565
- Testing
- ExAblate 2100
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- InSightec
Metastatic Breast Cancer
Evaluation of the Safety and Efficacy of THL-P in Metastatic Breast Cancer
The purpose of this study is to obtain evidence from test article with efficacy in Metastatic Breast Cancer patients. The average of all changes from baseline to post-treatment evaluations in global health/quality of life (QoL)…
- Trial name
- NCT00976365
- Testing
- THL-P
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Taiwan THL Co.LTd.
HER-2 Gene Amplification, HER2-positive Gastric Cancer
Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors
This is a Phase 1/2, open-label, multicenter, non-randomized study to investigate the safety, tolerability, and clinical activity of HER2-specific dual-switch CAR-T cells, BPX-603, administered with rimiducid to subjects with…
- Conditions
- HER-2 Gene Amplification, HER2-positive Gastric Cancer, HER2-positive Breast Cancer, HER-2 Protein Overexpression
- Trial name
- NCT04650451
- Testing
- chimeric antigen receptor (CAR) T cell therapy
- Where
- 7 sites in United States
- Volunteers
- 220 people
- Sponsor
- Bellicum Pharmaceuticals
Breast Neoplasms, Colorectal Neoplasms
Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors
This is a Phase 1 open-label study of SN2310 Injectable Emulsion in patients with advanced solid malignancies. The study is designed to determine the maximum tolerated dose and dose-limiting toxicity of SN2310 Injectable…
- Conditions
- Breast Neoplasms, Colorectal Neoplasms, Pancreatic Neoplasms, Pelvic Neoplasms
- Trial name
- NCT00385177
- Testing
- SN2310 Injectable Emulsion
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- Achieve Life Sciences
Breast Cancer
Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast Cancer
This is a single arm, modified dose escalation, open label trial with the objectives of: (1) Determining a safe optimal dose of INCB007839 in combination with trastuzumab and docetaxel (2) Determining clinical efficacy and safety…
- Trial name
- NCT00864175
- Testing
- INCB007839, trastuzumab, Docetaxel
- Where
- 12 sites in India
- Volunteers
- 68 people
- Sponsor
- Incyte Corporation
Breast Cancer
A Prospective Validation Study of a Rapid Point-of-Care Breath Test for Breast Cancer
This is a multicenter, blinded prospective study of 2,000 women undergoing mammography for breast -related symptoms or signs. Breath tests will be performed in order to demonstrate that the outcome of mammography results combined…
- Trial name
- NCT02888366
- Where
- 4 sites in United States
- Volunteers
- 500 people
- Sponsor
- Menssana Research, Inc.
Breast Cancer
Multi-Reader Multi-Case Controlled Clinical Trial to Assess the Fujifilm FFDM and DBT Reader Training Program
The purpose of this pilot is to assess the adequacy of the Fujifilm DBT Reader Study Training program to ensure that Readers participating in the Fujifilm DBT pivotal trial are properly trained in the reading and interpretation…
- Trial name
- NCT02685566
- Testing
- FFDM Plus DBT, FFDM
- Where
- 5 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Fujifilm Medical Systems USA, Inc.
Breast Cancer
A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer
This study will evaluate the effect of bevacizumab in combination with chemotherapy or endocrine therapy, as preoperative treatment, in participants with HER2 negative breast cancer.
- Trial name
- NCT00773695
- Testing
- Aromatase Inhibitor, Bevacizumab, Epirubicine
- Where
- 3 sites in Norway
- Volunteers
- 150 people
- Sponsor
- Hoffmann-La Roche
High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors.
- Conditions
- High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
- Trial name
- RAINFOL-01 (NCT05579366)
- Testing
- Rina-S, Carboplatin, Bevacizumab
- Where
- 66 sites in United States, China and 1 more
- Volunteers
- 952 people
- Sponsor
- Genmab
Neoplasms, Breast
Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer
This study was designed to evaluate and compare the safety and efficacy of an oral dual tyrosine kinase inhibitor, lapatinib, versus placebo in women with early-stage ErbB2-overexpressing breast cancer who have completed their…
- Trial name
- NCT00374322
- Testing
- lapatinib
- Where
- 439 sites in United States, Argentina and 31 more
- Volunteers
- 3,166 people
- Sponsor
- GlaxoSmithKline
Breast Neoplasms
A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer
To compare treatment with SU011248 plus paclitaxel versus bevacizumab plus paclitaxel to determine which treatment works better against breast cancer
- Trial name
- NCT00373256
- Testing
- Sunitinib, paclitaxel, bevacizumab
- Where
- 250 sites in United States, Germany and 2 more
- Volunteers
- 488 people
- Sponsor
- Pfizer
Breast Neoplasms
Research Of Quality Of Life And Safety Outcomes Of Postmenopausal Breast Cancer Patients Switching From Tamoxifen Therapy To Aromatase Inhibitor Therapy
The purpose of this study is to follow safety and quality of life outcomes on patients switching from tamoxifen therapy to aromatase inhibitor therapy.
- Trial name
- TAMARA (NCT00784888)
- Testing
- Aromatase inhibitors
- Where
- 16 sites in Turkey (Türkiye)
- Volunteers
- 344 people
- Sponsor
- Pfizer
Breast Neoplasms
A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)
The study is designed to compare the clinical benefit following treatment with letrozole in combination with PD-0332991 versus letrozole in combination with placebo in postmenopausal women with ER(+)/HER2(-) advanced breast…
- Trial name
- NCT01740427
- Testing
- PD-0332991, Letrozole
- Where
- 305 sites in United States, Australia and 16 more
- Volunteers
- 666 people
- Sponsor
- Pfizer
Osteoporosis, Postmenopausal
Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer
The purpose of this trial is to study: Effects of arzoxifene on bone fractures and bone mass. Effects of arzoxifene on getting breast cancer.
- Trial name
- NCT00088010
- Testing
- Arzoxifene
- Where
- United States
- Volunteers
- 9,369 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.